These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34719935)

  • 1. Towards next-generation personalization of tacrolimus treatment: a review on advanced diagnostic and therapeutic approaches.
    Radhakrishnan A; Kuppusamy G; Ponnusankar S; Mutalik S
    Pharmacogenomics; 2021 Nov; 22(17):1151-1175. PubMed ID: 34719935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theoretical Formulation Strategies towards Neutralizing Inter-individual Variability Associated with Tacrolimus Immunosuppressant Therapy: A Case Study on Nextgeneration Personalized Medicine.
    Radhakrishnan A; Kuppusamy G
    Curr Drug Metab; 2021; 22(12):939-956. PubMed ID: 34779367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.
    Wallemacq P; Armstrong VW; Brunet M; Haufroid V; Holt DW; Johnston A; Kuypers D; Le Meur Y; Marquet P; Oellerich M; Thervet E; Toenshoff B; Undre N; Weber LT; Westley IS; Mourad M
    Ther Drug Monit; 2009 Apr; 31(2):139-52. PubMed ID: 19177031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus Dose Optimization Strategy for Refractory Ulcerative Colitis Based on the Cytochrome P450 3A5 Polymorphism Prediction Using Trough Concentration after 24 Hours.
    Onodera M; Endo K; Naito T; Moroi R; Kuroha M; Kanazawa Y; Kimura T; Shiga H; Kakuta Y; Negoro K; Kinouchi Y; Shimosegawa T
    Digestion; 2018; 97(1):90-96. PubMed ID: 29393157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical approach to solving discrepancies in therapeutic drug monitoring results for patients on sirolimus or tacrolimus: Towards personalized medicine, immunosuppression and pharmacogenomics.
    Millner L; Rodriguez C; Jortani SA
    Clin Chim Acta; 2015 Oct; 450():15-8. PubMed ID: 26232156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.
    Provenzani A; Santeusanio A; Mathis E; Notarbartolo M; Labbozzetta M; Poma P; Provenzani A; Polidori C; Vizzini G; Polidori P; D'Alessandro N
    World J Gastroenterol; 2013 Dec; 19(48):9156-73. PubMed ID: 24409044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomic phase transition from personalized medicine to patient-centric customized delivery.
    Radhakrishnan A; Kuppusamy G; Ponnusankar S; Shanmukhan NK
    Pharmacogenomics J; 2020 Feb; 20(1):1-18. PubMed ID: 31819163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management.
    Soni A; Gowthamarajan K; Radhakrishnan A
    Int J Pharm Compd; 2018; 22(2):108-121. PubMed ID: 29877858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.
    Brunet M; van Gelder T; Åsberg A; Haufroid V; Hesselink DA; Langman L; Lemaitre F; Marquet P; Seger C; Shipkova M; Vinks A; Wallemacq P; Wieland E; Woillard JB; Barten MJ; Budde K; Colom H; Dieterlen MT; Elens L; Johnson-Davis KL; Kunicki PK; MacPhee I; Masuda S; Mathew BS; Millán O; Mizuno T; Moes DAR; Monchaud C; Noceti O; Pawinski T; Picard N; van Schaik R; Sommerer C; Vethe NT; de Winter B; Christians U; Bergan S
    Ther Drug Monit; 2019 Jun; 41(3):261-307. PubMed ID: 31045868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Individualized dosage regimen of immunosuppressive drugs based on pharmacokinetic and pharmacodynamic analysis].
    Fukudo M
    Yakugaku Zasshi; 2007 Jul; 127(7):1081-9. PubMed ID: 17603267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.
    Tang JT; Andrews LM; van Gelder T; Shi YY; van Schaik RH; Wang LL; Hesselink DA
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):555-65. PubMed ID: 27010623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies.
    Anglicheau D; Legendre C; Thervet E
    Transplant Proc; 2007 Sep; 39(7):2142-4. PubMed ID: 17889118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "What do we know about tacrolimus pharmacogenetics in transplant recipients?".
    Kuypers DR
    Pharmacogenomics; 2018 May; 19(7):593-597. PubMed ID: 29701126
    [No Abstract]   [Full Text] [Related]  

  • 14. Toward personalized medicine in renal transplantation.
    Lampreabe I; Gainza de los Rios FJ; Arrieta Gutiérrez A; Jofre-Monseny L; Rodriguez M; Amenabar Iribar JJ; Zárraga Larrondo S; Tejedor D; Martinez A; Olano-Martin E
    Transplant Proc; 2010 Oct; 42(8):2864-7. PubMed ID: 20970553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future of pharmacogenetics-based therapy for tuberculosis.
    Matsumoto T; Ohno M; Azuma J
    Pharmacogenomics; 2014 Apr; 15(5):601-7. PubMed ID: 24798717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose optimization of tacrolimus with therapeutic drug monitoring and CYP3A5 polymorphism in patients with myasthenia gravis.
    Chen D; Hou S; Zhao M; Sun X; Zhang H; Yang L
    Eur J Neurol; 2018 Aug; 25(8):1049-e80. PubMed ID: 29611886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic considerations.
    Zhang X; Lin G; Tan L; Li J
    Biomed Pharmacother; 2018 Jun; 102():107-114. PubMed ID: 29550633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation.
    Thervet E; Anglicheau D; Legendre C; Beaune P
    Ther Drug Monit; 2008 Apr; 30(2):143-50. PubMed ID: 18367973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus pharmacodynamics and pharmacogenetics along the calcineurin pathway in human lymphocytes.
    Noceti OM; Woillard JB; Boumediene A; Esperón P; Taupin JL; Gerona S; Valverde M; Touriño C; Marquet P
    Clin Chem; 2014 Oct; 60(10):1336-45. PubMed ID: 25142246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
    Khaled SK; Palmer JM; Herzog J; Stiller T; Tsai NC; Senitzer D; Liu X; Thomas SH; Shayani S; Weitzel J; Forman SJ; Nakamura R
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):268-276. PubMed ID: 26325438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.